Monitoring the safety of quadrivalent human papillomavirus vaccine: findings from the Vaccine Safety Datalink.
about
Enhancing vaccine safety capacity globally: A lifecycle perspectiveThe "HPV Discussion": Effective Use of Data to Deliver Recommendations to Patients Impacted by HPVSafety monitoring in the Vaccine Adverse Event Reporting System (VAERS)Near real-time vaccine safety surveillance using electronic health records-a systematic review of the application of statistical methodsCurrent global status & impact of human papillomavirus vaccination: Implications for IndiaLong-term efficacy and safety of human papillomavirus vaccinationSafety of human papillomavirus vaccines: a reviewAutoimmune, neurological, and venous thromboembolic adverse events after immunisation of adolescent girls with quadrivalent human papillomavirus vaccine in Denmark and Sweden: cohort studyInadvisable anti-vaccination sentiment: Human Papilloma Virus immunisation falsely under the microscope.Annual Report to the Nation on the Status of Cancer, 1975-2009, featuring the burden and trends in human papillomavirus(HPV)-associated cancers and HPV vaccination coverage levelsEvaluating Social Media Networks in Medicines Safety Surveillance: Two Case StudiesA Synthesis of Current Surveillance Planning Methods for the Sequential Monitoring of Drug and Vaccine Adverse Effects Using Electronic Health Care Data.Safety of human papillomavirus vaccines: a review.Quadrivalent HPV vaccine safety review and safety monitoring plans for nine-valent HPV vaccine in the United StatesSafety of a meningococcal group B vaccine used in response to two university outbreaks.A comparison of active adverse event surveillance systems worldwide.Guillain-Barre syndrome following quadrivalent human papillomavirus vaccination among vaccine-eligible individuals in the United States.HPV vaccination to prevent cervical cancer and other HPV-associated disease: from basic science to effective interventions.Examining a possible association between human papilloma virus (HPV) vaccination and migraine: results of a cohort study in the NetherlandsParents' decision-making about the human papillomavirus vaccine for their daughters: I. Quantitative results.Adolescent Premature Ovarian Insufficiency Following Human Papillomavirus Vaccination: A Case Series Seen in General PracticeEffects of a Presidential Candidate's Comments on HPV VaccineAbsence of venous thromboembolism risk following quadrivalent human papillomavirus vaccination, Vaccine Safety Datalink, 2008-2011.High school females and those with other vaccinations most likely to complete the Human Papillomavirus vaccineVaccination against HPV-Associated Neoplasias: Recommendations from the Current S3 Guideline of the HPV Management Forum of the Paul-Ehrlich Society - AWMF Guidelines, Registry No. 082-002 (short version), valid until Dec. 31st, 2018Human papillomavirus vaccine uptake, knowledge and attitude among 10th grade students in Berlin, Germany, 2010.Low HPV vaccine coverage among female community college students.Impact of 2-, 4- and 9-valent HPV vaccines on morbidity and mortality from cervical cancerEfficacy and safety of human papillomavirus vaccine for primary prevention of cervical cancer: A review of evidence from phase III trials and national programs.Risk of new onset autoimmune disease in 9- to 25-year-old women exposed to human papillomavirus-16/18 AS04-adjuvanted vaccine in the United Kingdom.Acceptability of HPV vaccine for males and preferences for future education programs among Appalachian residents.Active surveillance for adverse events following immunization.Human papillomavirus vaccination: where are we now?Quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine (gardasil(®)): a review of its use in the prevention of premalignant anogenital lesions, cervical and anal cancers, and genital warts.The safety of human papilloma virus-blockers and the risk of triggering autoimmune diseases.9-Valent HPV vaccine for cancers, pre-cancers and genital warts related to HPV.Prophylactic HPV vaccination: past, present, and future.Safety of Human Papillomavirus 9-Valent Vaccine: A Meta-Analysis of Randomized TrialsEvaluation of optic neuritis following human papillomavirus vaccination.HPV vaccine completion and dose adherence among commercially insured females aged 9 through 26 years in the US.
P2860
Q26782451-5791F4C6-10C5-4592-BAB0-98AED6DB58FEQ26798297-C5C61A37-C386-479A-9F9B-B4FBC6935D2DQ26799634-46330570-282E-47D9-AF52-C4CFA611F333Q28075754-FEDFC943-C258-4D61-9AC3-07672E1E6C9AQ28079776-47D90A2B-209A-499B-BE26-36590E24D8EAQ28081156-AD0CD2F6-32FF-40BD-A793-6605F26B5325Q28082119-D427FFD7-1356-4296-AE22-DB092231503BQ28300023-D2E38718-6BCE-42E3-9345-09D7203B8BA5Q30275602-C1752E4B-BA87-4400-B4B5-D7E69558E938Q30534669-F50A50B5-36B4-45A3-B2CB-B7611835092BQ30665207-F1676FE7-B677-4026-81F2-31B83C18BCFDQ31135365-0BFA6AB1-155E-4262-A3FE-D8309927E595Q33162724-1480D2A6-4BD1-4FAC-B8E7-CB9D9DFCC5D9Q33166996-683E812D-9B6F-4B68-99C6-75664D948BDBQ33168484-BEE9C40B-297C-4E09-8983-81B3C0982658Q34051880-CE2D47CD-05D5-46FB-BEF7-F7330F20DF2DQ34271547-02CC61F3-13C1-417B-81F9-D8FAEAF02643Q34507291-F5342000-D226-4E87-A5B4-011E6CEA3D4DQ35546272-7BD6C456-C6C7-4C3D-996D-DCE076F4A872Q35887140-59221B5E-66E7-4CD3-BB21-6B61B09FA07AQ35927665-4E4A942C-751B-46F2-B26F-9061A1D4EF73Q36420826-A297FF4D-1063-428C-A1C9-6570B971D357Q36457330-2CBA27AE-CB46-4116-A877-BD8B6A58CA75Q36486428-F6075CB8-93DD-45ED-9213-A6D64C029F91Q36743080-6A5FFDAB-900D-4379-8E6A-CE87D03D1F93Q36888044-190BD84E-EF2F-4E5B-9476-D9B45CA1F5A9Q37106257-B0824E46-6CC4-4C83-987C-127928DAF9B4Q37135163-863AF171-A22C-4877-8259-0FCEDC22213FQ37467138-4B50BDC7-155A-4E64-B548-960A6A2A2EEAQ37473234-D5107828-395A-4128-AEB6-498F24962CF9Q37704809-ADDB9C21-E903-46A5-B599-9EF7D0C71DBEQ38172268-B1C5CD10-C22C-4070-9755-99F1459FB19BQ38218612-8A054A88-F813-4829-AF38-0DDAA76E0508Q38229304-BEE99175-298F-487D-9C3D-CA21989F9A99Q38555725-93330CB9-E15D-4CD6-B71B-303C359CA160Q38586257-62345011-F4EC-4ED9-A866-3FEE4A191341Q38597567-11352267-F1CA-418B-9AE0-E3A6CA1D22A8Q38622756-89355357-5EC3-4D18-96BA-421DD0ACD0B1Q38809091-1F2AA7F4-7C69-4C6F-92EE-9C033B11C2D2Q40256932-E7C2CF97-AAB0-4414-BED6-9AE5488AE363
P2860
Monitoring the safety of quadrivalent human papillomavirus vaccine: findings from the Vaccine Safety Datalink.
description
2011 nî lūn-bûn
@nan
2011 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Monitoring the safety of quadr ...... m the Vaccine Safety Datalink.
@ast
Monitoring the safety of quadr ...... m the Vaccine Safety Datalink.
@en
type
label
Monitoring the safety of quadr ...... m the Vaccine Safety Datalink.
@ast
Monitoring the safety of quadr ...... m the Vaccine Safety Datalink.
@en
prefLabel
Monitoring the safety of quadr ...... m the Vaccine Safety Datalink.
@ast
Monitoring the safety of quadr ...... m the Vaccine Safety Datalink.
@en
P2093
P50
P1433
P1476
Monitoring the safety of quadr ...... om the Vaccine Safety Datalink
@en
P2093
Bruce Fireman
Edwin Lewis
Eric S Weintraub
Irene Shui
Julianne Gee
Matthew F Daley
Nicola P Klein
Ruihua Yin
P304
P356
10.1016/J.VACCINE.2011.08.106
P407
P577
2011-09-09T00:00:00Z